Biotech

All Articles

OS Treatments refiles $6M IPO to money HER2 medicine, preclinical ADCs

.OS Therapies will certainly list on the NYSE American sell swap this morning through a $6.4 thousan...

ALX's fizzling CD47 feedback price sends stock spiraling down

.ALX Oncology's stage 2 stomach cancer cells response price has deteriorated. After finding its CD47...

Ionis axes eye condition coming from intendeds of Roche-partnered prospect after data disappoint

.An Additional of Ionis Pharmaceuticals' essential midphase readouts has actually fallen short of de...

Biogen's CEO stated no dangerous deals in 2023. He's ready to become daring

.While Biogen's pharma peers are seeking for late-stage possessions with little bit of danger, CEO C...

Instil refills pipe in $2B biobucks take care of ImmunOnco

.Instil Biography has actually been actually a biotech seeking a pipe after it ditched its lead reso...

Biogen bows out Denali Alzheimer's collab

.Biogen has actually returned civil liberties to an early Alzheimer's disease program to Denali Ther...

Takeda faucets brand new mind people oncology company-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of notable leadership hirings, shootings and als...

Vertex, beaten through AATD once again, loses 2 assets on throw out stack

.Vertex's attempt to deal with an uncommon hereditary disease has actually struck another trouble. T...

Vir increases 3 T-cell engagers coming from Sanofi, lays off 25% of personnel

.Vir Medical's second-quarter earnings record wasn't except major news. The firm accepted a trio of ...

Galapagos pauses CAR-T cell treatment trial over Parkinsonism situation

.Galapagos has paused enrollment in a trial of a BCMA-directed CAR-T tissue treatment, pumping the b...